Cisatracurium besylate
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Cisatracurium besylate
- Generic name
- CISATRACURIUM BESYLATE
- Manufacturer
- Slate Run Pharmaceuticals, LLC
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 49185e78-d244-4426-90ef-ad109824eddb
- SPL ID
- 20cd9789-700a-5fa0-e063-6394a90a5d0d
- Version
- 2
- Effective date
- 2024-08-29
- Source export date
- 2026-11-13
- Source partition
- 5
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0005-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/e10f1fd48195fb7eda0be611a6e3c49a40fe34c69a9c2a8d9e3e3b897ac31621/drug-label-0005-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 16:04:28
| Harmonized routes |
|---|
| INTRAVENOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 216539 | derived:openfda.application_number |
| application number | ANDA216539 | openfda.application_number | |
| brand name | Cisatracurium besylate | openfda.brand_name | |
| generic name | CISATRACURIUM BESYLATE | openfda.generic_name | |
| manufacturer name | Slate Run Pharmaceuticals, LLC | openfda.manufacturer_name | |
| ndc | package | 70436-112-82 | openfda.package_ndc |
| ndc | package | 70436-114-82 | openfda.package_ndc |
| ndc | product | 70436-114 | openfda.product_ndc |
| ndc | product | 70436-112 | openfda.product_ndc |
| ndc11 | package | 70436011282 | derived:openfda.package_ndc |
| ndc11 | package | 70436011482 | derived:openfda.package_ndc |
| rxcui | 1730194 | openfda.rxcui | |
| rxcui | 199212 | openfda.rxcui | |
| spl id | 20cd9789-700a-5fa0-e063-6394a90a5d0d | id | |
| spl set id | 49185e78-d244-4426-90ef-ad109824eddb | set_id | |
| unii | 80YS8O1MBS | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5.9 Resistance to Neuromuscular Blockade with Certain Drugs Shorter durations of neuromuscular block may occur and Cisatracurium Besylate Injection infusion rate requirements may be higher in patients chronically administered phenytoin or carbamazepine [see Drug Interactions ( 7.1 ) and Clinical Pharmacology ( 12.3 )] . Use peripheral nerve stimulation and monitor the clinical signs of neuromuscular blockade to determine the adequacy of neuromuscular blockage and the need to adjust the Cisatracurium Besylate Injection dosage.
warnings and cautions
5.10 Malignant Hyperthermia (MH) Cisatracurium Besylate Injection has not been studied in MH-susceptible patients. Because MH can develop in the absence of established triggering agents, the clinician should be prepared to recognize and treat MH in any patient undergoing general anesthesia.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The most common adverse reactions (0.1% to 0.4%) were bradycardia, hypotension, flushing, bronchospasm, and rash. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Slate Run Pharmaceuticals, LLC at 1-888-341-9214 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Studies Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. Adverse Reactions in Clinical Trials of Cisatracurium Besylate Injection in Surgical Patients The data presented below are based on studies involving 945 surgical patients who received Cisatracurium Besylate Injection in conjunction with other drugs in US and European clinical studies in a variety of procedures [see Clinical Studies ( 14.1 )] . Table 3 displays adverse reactions that occurred at a rate of less than 1%. Table 3. Adverse Reactions in Clinical Trials of Cisatracurium Besylate Injection in Surgical Patients Adverse Reaction Incidence Bradycardia 0.4% Hypotension 0.2% Flushing 0.2% Bronchospasm 0.2% Rash 0.1% Adverse Reactions in Clinical Trials of Cisatracurium Besylate Injection in Intensive Care Unit Patients The adverse reactions presented below were from studies involving 68 adult ICU patients who received Cisatracurium Besylate Injection in conjunction with other drugs in US and European clinical studies [see Clinical Studies ( 14.3 )] . One patient experienced bronchospasm. In one of the two ICU studies, a randomized and double-blind study of ICU patients using TOF neuromuscular monitoring, there were two reports of prolonged recovery (range: 167 and 270 minutes) among 28 patients administered Cisatracurium Besylate Injection and 13 reports of prolonged recovery (range: 90 minutes to 33 hours) among 30 patients administered vecuronium. 6.2 Postmarketing Experience The following events have been identified during post-approval use of Cisatracurium Besylate Injection in conjunction with one or more anesthetic agents in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to Cisatracurium Besylate Injection: anaphylaxis, histamine release, prolonged neuromuscular block, muscle weakness, myopathy.
adverse reactions
6.1 Clinical Studies Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. Adverse Reactions in Clinical Trials of Cisatracurium Besylate Injection in Surgical Patients The data presented below are based on studies involving 945 surgical patients who received Cisatracurium Besylate Injection in conjunction with other drugs in US and European clinical studies in a variety of procedures [see Clinical Studies ( 14.1 )] . Table 3 displays adverse reactions that occurred at a rate of less than 1%. Table 3. Adverse Reactions in Clinical Trials of Cisatracurium Besylate Injection in Surgical Patients Adverse Reaction Incidence Bradycardia 0.4% Hypotension 0.2% Flushing 0.2% Bronchospasm 0.2% Rash 0.1% Adverse Reactions in Clinical Trials of Cisatracurium Besylate Injection in Intensive Care Unit Patients The adverse reactions presented below were from studies involving 68 adult ICU patients who received Cisatracurium Besylate Injection in conjunction with other drugs in US and European clinical studies [see Clinical Studies ( 14.3 )] . One patient experienced bronchospasm. In one of the two ICU studies, a randomized and double-blind study of ICU patients using TOF neuromuscular monitoring, there were two reports of prolonged recovery (range: 167 and 270 minutes) among 28 patients administered Cisatracurium Besylate Injection and 13 reports of prolonged recovery (range: 90 minutes to 33 hours) among 30 patients administered vecuronium.
adverse reactions
6.2 Postmarketing Experience The following events have been identified during post-approval use of Cisatracurium Besylate Injection in conjunction with one or more anesthetic agents in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to Cisatracurium Besylate Injection: anaphylaxis, histamine release, prolonged neuromuscular block, muscle weakness, myopathy.
adverse reactions table
<table ID="_Reftable_3" width="80%"><caption>Table 3. Adverse Reactions in Clinical Trials of Cisatracurium Besylate Injection in Surgical Patients</caption><col width="45%"/><col width="45%"/><tbody><tr><td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top"><paragraph><content styleCode="bold">Adverse Reaction</content></paragraph></td><td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top"><paragraph><content styleCode="bold">Incidence</content></paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Bradycardia</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>0.4%</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Hypotension</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>0.2%</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Flushing</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>0.2%</paragraph></td></tr><tr><td styleCode="Rrule Lrule Botrule " valign="top"><paragraph>Bronchospasm</paragraph></td><td align="center" styleCode="Rrule Lrule Botrule " valign="top"><paragraph>0.2%</paragraph></td></tr><tr><td styleCode="Rrule Botrule Lrule " valign="top"><paragraph>Rash</paragraph></td><td align="center" styleCode="Rrule Botrule Lrule " valign="top"><paragraph>0.1%</paragraph></td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.